IMA IMA
Company Profile ↓Company Overview
IMA (IMA) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.02.
Recent Developments
- Dec 2025 Revenue of $800.00K (-77.1% YoY); net profit $-45.35M.
- Trailing 12 Months Year-on-year growth — revenue -77.1%.
- 5-Year Trend Long-term compounding — revenue CAGR -38.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -38.64% |
| 1 Year: | -77.14% |
Stock Price Performance
| 1 Year: | -65.36% |
| 6 Months: | -18.32% |
| 3 Months: | -1.37% |
| 1 Month: | -5.27% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)50.00 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -38.6% CAGR over 5 years.
- Trading 65.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.23M | 3.07M | 2.83M | 3.47M | 3.55M | 3.75M | 3.38M | 382.00K | 6.40M | 5.31M | 2.00M | 1.19M | - | - | 3.50M | 800.00K | - | - | - |
| Operating Income | -7.18M | -5.06M | -6.23M | -9.72M | -12.69M | -14.52M | -16.96M | -20.95M | -17.88M | -15.52M | -18.49M | -19.50M | -18.23M | -15.82M | -2.04M | -6.00M | -8.75M | -26.59M | -12.08M |
| Net Income | -6.95M | -5.04M | -6.22M | -9.72M | -12.68M | -14.52M | -16.84M | -20.49M | -17.34M | -14.22M | -17.11M | -17.34M | -22.31M | -6.26M | -3.18M | -6.08M | -7.58M | -24.78M | -10.62M |
| Diluted EPS | - | - | - | - | -0.35 | -0.40 | -0.47 | -0.57 | -0.48 | -0.39 | -0.44 | -0.40 | -0.33 | -0.28 | -2.58 | -3.80 | -0.06 | -2.91 | -0.95 |
| R&D Expense | 7.89M | 6.33M | 7.22M | 10.02M | 11.37M | 13.38M | 14.34M | 15.49M | 18.85M | 15.55M | 15.17M | 14.65M | 9.64M | 9.83M | 3.88M | 4.04M | 4.03M | 15.56M | 5.96M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 9.19M | 30.98M | 15.62M | 9.16M | 3.50M | 800.00K |
| Operating Income | -44.52M | -34.14M | -70.90M | -75.42M | -37.00M | -48.45M |
| Net Income | -44.26M | -34.12M | -68.77M | -68.17M | -36.57M | -45.35M |
| Diluted EPS | - | -1.22 | -1.90 | -1.63 | -22.10 | -9.64 |
| R&D Expense | 44.85M | 47.11M | 64.32M | 59.65M | 32.11M | 28.52M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 168.40M | 247.88M | 172.26M | 192.09M | 15.92M | 152.98M |
| Total Equity | -61.46M | -101.05M | 207.88M | 146.97M | -126.11M | -160.56M | 133.14M |
| Cash & Equivalents | - | 162.49M | 232.22M | 59.92M | 119.89M | 12.12M | 94.53M |
| Total Liabilities | - | 63.47M | 40.00M | 25.29M | 22.34M | 17.45M | 19.84M |
| Current Liabilities | - | 28.33M | 27.19M | 21.50M | 14.21M | 17.21M | 11.23M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -37.83M | -60.25M | -74.11M | -79.74M | -21.32M | -47.84M |
| Investing Cash Flow | 2.92M | -1.76M | -99.28M | 64.14M | 11.12M | -5.81M |
| Financing Cash Flow | 116.18M | 131.74M | 1.09M | 75.98M | 6.91M | 135.47M |
| Capital Expenditure | -766.00K | -1.76M | -1.43M | -414.00K | - | - |
| Free Cash Flow | -38.59M | -62.01M | -75.54M | -80.16M | - | - |
| Share Buybacks | - | - | - | 663.00K | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -484.2% | -110.2% | -454.0% | -823.3% | -1,057.1% | -6,056.4% |
| Net Margin % | -481.4% | -110.1% | -440.3% | -744.2% | -1,044.8% | -5,668.6% |
| ROE % | 43.8% | -16.4% | -46.8% | 54.1% | 22.8% | -34.1% |
| ROCE % | -31.8% | -15.5% | -47.0% | -42.4% | 2,874.9% | -34.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IMA
ImageneBio’s Atopic Dermatitis Data Anticipated in Q4 2027 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxPOVpTRXhwYjVFUTlSdjRJaHFvYXphaUdFQ3pBbXE4aGhJd21TUmEzM28xZU9QbXFfNnc5RFgyaVBkQ0dXaHgxN3A3Ull0LUFLdVNuRVRvWXBRaHFmZkh6dDdjSnJXN0hxcDc4THBGWHA3dXZpU3ZmYlBSYlFEYWVmNGEycnNrMmJuTHZ5LT…
ImageneBio Reports Second Quarter 2026 Financial Results and Corporate Update on Olevaprubart Clinical Development - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxNU1o3TGdQdklLanFoOWd5T0VFS1JBRjQtSFF5ajZURWR2a1lpRWM1WU0xU1NDM2doZzEycHdfZ1BnZVV5QTlPem44RW1Td2VwVVRncFVRTHJVOFJONlhFWHd2VVNEWTVSSk5MMXYtUUd4SVpQNV9lcU9fUGJBUGx3ZUFjMWdEOWxiamFlbF…
IMA Stock Surges 24%, Breaks 50-DMA For First Time Since February – What's Driving The Rally? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNN0ZQbEVfSTd4NmhxcUlwN3Y2Z1NLSnlEU20zWGJfMjlHUVpiakVXRDhMRm94QU83WnA4elREZ19GMlBVeU5NdUFSN0R0TndEcjBCOTljelZ5RzRKeVB6N3A5cEVLQmpTZWpLbzlHS0gxU05ZT0lMRlB3VlFQU0dScl9wcG5lNF94Y2pXbX…
ImageneBio, Inc. Revenue Breakdown – NASDAQ:IMA - TradingView
<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTE1RU19wMUxpNTRkRnl2c21zSUhzZFk4aHZVMG50MEgxQThIUkYzanNnSVd6b19nUHdRV2JpbHhrUFFwVjV2VGhZSlBBUGhhVGZMSUZxWEJWbE1WNUdSQTZWdDV6OHNkMlplWm4yYUN3ZzJweVZ1d0E?oc=5" target="_blank">ImageneB…
American Tungsten Stock Extends Green Momentum as IMA Mine Expansion and US Critical-Mineral Demand Strengthen Optimism - kalkine.ca
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxNVFR2V1JxUVI0NDdaS2J2NEZVaGJSQXJOYkpLOW1zM2VQTk91Si1lSnRDS19SZVQyOVhJSWdEZHRsSmR5RDlsY3RoVXJQS0xOQlJlUWhmc3dJZ3dRRE1fUnFoRTlmWm9qc0VFMFo3M1lIX1BnTUNaUGtEbUZtdm5BZmJzRHhnWDQxQ1pyTj…
Insider Buyers Lose Additional US$9.8k As ImageneBio Dips To US$61m - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxQTGJjY2FMS0k1YVJLMGMwSWl5MzA3alA1a3UyWVJRZUw4bzIwU3pialpvSGV5UDRsdVZhYkVRanJSMFc1T0lUTGpza0VvV3hLTVZCbWZ5MUs5cEtWdVlyUUpCMnZFVEVvRklMa2NTcU1kMXoxSm8zZ0hmLUttS3RRTkpGTENIVDBPUi1VUk…
IMA — Frequently Asked Questions
What is the current share price of IMA?
As of 2026-08-05 17:25 PDT, IMA trades at $5.75 on NASDAQ/NYSE. Its 52-week range is $4.55 to $16.60.
What is the P/E ratio of IMA?
IMA trades at a trailing price-to-earnings (P/E) ratio of -0.60.
What is the return on equity (ROE) of IMA?
IMA has a return on equity (ROE) of -34.06%. Its return on capital employed (ROCE) is -34.18%.
Is IMA a good stock to buy?
This page provides a data-driven analysis of IMA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.